HITTING the Diagnosis

Fenelus, Maly; Peerschke, Ellinor I.B.

doi:10.1093/ajcp/aqy040

Cited by 2 publications

(1 citation statement)

References 18 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1. Its incidence and mortality are increasing rapidly and it is also one of the malignant tumors with the worst prognosis [ 10 ]. For this reason, more and more attention and urgency are being given to treatments relevant to lung cancer.…”

Section: Introductionmentioning

confidence: 99%

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Wang

Shao

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Even though cytopenia caused by either chemotherapy or radiotherapy is a common complication in cancer patients, chemoradiotherapy remains an essential treatment for the majority of patients. The purpose of this study was to look into the clinical efficacy and cost-effectiveness of recombinant human thrombopoietin (rhTPO) in treating chemo- or chemoradiotherapy-induced grade II, III, and IV thrombocytopenia. From December 2019 to November 2020, 233 lung cancer patients admitted to our hospital with chemotherapy- or chemoradiotherapy-induced thrombocytopenia were enrolled and treated with rhTPO. The study's findings revealed a significant disparity in the use of concurrent chemoradiotherapy in patients with grade II, III, and IV thrombocytopenia. All costs, including rhTPO treatment costs, platelet costs, drug costs, and nondrug costs, tended to rise as the severity of thrombocytopenia increased. In the treatment of chemotherapy or radiotherapy-induced thrombocytopenia, rhTPO has shown good clinical efficacy. In the treatment of grade II thrombocytopenia, rhTPO has a favorable economic evaluation. As a result, early intervention and thrombocytopenia treatment should be provided, which warrants further clinical investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Wang

Shao

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

Heparin‐induced thrombocytopenia and thrombosis in primary lymphedema patients who underwent vascularized lymph node transplantations

Hsu

Lin

Cheng

2022

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundHeparin‐induced thrombocytopenia and thrombosis (HITT) may result in microsurgical flap failure. This study investigated the outcomes of HITT in primary lymphedema patients who underwent vascularized lymph node transplantations (VLNT).MethodsBetween 2012 and 2019, primary lymphedema patients who underwent VLNTs were retrospectively included. The 4Ts score was used to categorize patients into HITT (scores of 5–7) and non‐HITT (score < 5) groups. Outcome evaluations included the re‐exploration rate, success rate, circumferential differences, cellulitis episodes, and Lymphedema Specific Quality of Life Questionnaire (LYMQoL) scores.ResultsTwenty‐six and 15 patients with 31 and 16 VLNTs were included in the HITT and non‐HITT groups, respectively. The HITT group had significantly greater first, second and third re‐exploration rates of 38.7% (12/31), 25.7% (8/31), and 6.5% (2/31) than the non‐HITT group (6.3%, 0%, and 0%, all p < 0.01), respectively. The platelet counts significantly decreased by 21.0% in the HITT group compared with the non‐HITT group (14%) on postoperative Day one (p < 0.01) with a cutoff value of 17% and AUC = 0.88.ConclusionsHITT may cause a high re‐exploration rate of VLNTs in primary lymphedema patients. The 17% reduction in platelets on postoperative day one was an early sign for detecting HITT.

show abstract

HITTING the Diagnosis

Abstract: HIT can be ruled out in cancer patients (negative predictive value and sensitivity = 100%) with low pretest probability, defined by 4Ts scores of 2 or less, significantly reducing the need for laboratory testing in this patient population.

Cited by 2 publications

References 18 publications

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy‐Induced Thrombocytopenia

Heparin‐induced thrombocytopenia and thrombosis in primary lymphedema patients who underwent vascularized lymph node transplantations

Contact Info

Product

Resources

About